Raymond James Financial Services Advisors Inc. raised its holdings in Antares Pharma, Inc. (NASDAQ:ATRS) by 40.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 133,900 shares of the specialty pharmaceutical company’s stock after acquiring an additional 38,475 shares during the period. Raymond James Financial Services Advisors Inc. owned about 0.09% of Antares Pharma worth $434,000 at the end of the most recent quarter.
A number of other institutional investors have also added to or reduced their stakes in the business. National Planning Corp grew its position in Antares Pharma by 11.5% in the second quarter. National Planning Corp now owns 58,233 shares of the specialty pharmaceutical company’s stock valued at $186,000 after acquiring an additional 6,000 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its stake in shares of Antares Pharma by 10.2% during the first quarter. Schwab Charles Investment Management Inc. now owns 289,093 shares of the specialty pharmaceutical company’s stock valued at $822,000 after purchasing an additional 26,847 shares in the last quarter. MML Investors Services LLC boosted its stake in shares of Antares Pharma by 228.2% during the second quarter. MML Investors Services LLC now owns 43,147 shares of the specialty pharmaceutical company’s stock valued at $139,000 after purchasing an additional 30,000 shares in the last quarter. Alliancebernstein L.P. acquired a new stake in shares of Antares Pharma during the second quarter valued at about $119,000. Finally, Legal & General Group Plc acquired a new stake in shares of Antares Pharma during the second quarter valued at about $120,000. Hedge funds and other institutional investors own 34.62% of the company’s stock.
Shares of Antares Pharma, Inc. (ATRS) opened at $1.73 on Thursday. Antares Pharma, Inc. has a 12 month low of $1.58 and a 12 month high of $4.09. The company has a current ratio of 3.34, a quick ratio of 2.89 and a debt-to-equity ratio of 0.69.
Antares Pharma (NASDAQ:ATRS) last announced its quarterly earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.03). Antares Pharma had a negative return on equity of 43.05% and a negative net margin of 32.06%. The firm had revenue of $15.10 million for the quarter, compared to analyst estimates of $14.01 million. Antares Pharma’s revenue was up 11.9% compared to the same quarter last year. research analysts anticipate that Antares Pharma, Inc. will post -0.11 earnings per share for the current year.
A number of brokerages have recently commented on ATRS. HC Wainwright set a $5.00 price target on Antares Pharma and gave the company a “buy” rating in a research note on Friday, October 13th. Piper Jaffray Companies reissued a “buy” rating on shares of Antares Pharma in a research note on Friday, September 8th. Finally, ValuEngine lowered Antares Pharma from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and two have given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $3.84.
In related news, Director Leonard S. Jacob sold 230,000 shares of Antares Pharma stock in a transaction that occurred on Monday, October 9th. The stock was sold at an average price of $4.05, for a total value of $931,500.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Thomas J. Garrity sold 30,000 shares of Antares Pharma stock in a transaction that occurred on Tuesday, October 3rd. The stock was sold at an average price of $3.50, for a total value of $105,000.00. The disclosure for this sale can be found here. 11.60% of the stock is owned by insiders.
ILLEGAL ACTIVITY NOTICE: “Antares Pharma, Inc. (ATRS) Holdings Lifted by Raymond James Financial Services Advisors Inc.” was first published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.thestockobserver.com/2017/12/07/antares-pharma-inc-atrs-holdings-lifted-by-raymond-james-financial-services-advisors-inc.html.
About Antares Pharma
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.
Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.